Non-executive director Steve Couldwell has been named as the new chief executive of Tissue Regenix Group PLC (LON:TRX), the regenerative medicines company.
Couldwell has more than 25 years of experience in the pharmaceutical and medical device industry.
READ: Tissue Regenix on hunt for new chief executive as Odell steps down
He was previously chief operating officer at Global Sanofi Biosurgery, with responsibility for strategy and execution for global business.
Tissue’s chairman, John Samuel, said Couldwell has an exceptional track record of growing businesses.
READ: Tissue Regenix sees revenues double in ‘transformational’ first half
"Since being appointed to the board in 2013 I have been impressed with the great commercial potential of our dCELL platform. The recent acquisition of CellRight Technologies has increased the market potential and provided a highly complementary product range in the $1.7bn US bone graft and substitute market,” Couldwell said.